The mechanisms underlying the hypoxic most cancers cell-mediated differentiation of cancer-associated fibroblasts (CAFs) haven’t been elucidated but. The current examine confirmed that the hypoxic head and neck squamous cell carcinoma (HNSCC) cells promoted CAF-like differentiation via secreting TGF-β and small extracellular vesicles (sEVs) that include enhanced ranges of miR-192/215 household miRNAs. Caveolin-1 (CAV1), which is a goal gene of miR-192/215, inhibited the TGF-β/SMAD signaling and promoted CAF-like differentiation of the fibroblasts. Restoring the degrees of CAV1 inhibited the hypoxic sEV- and TGF-β-induced CAF-like differentiation.
The enhanced ranges of miR-192/215 encapsulated in the HNSCC tissue-derived sEVs (however not serum-derived sEVs) indicated hypoxic and aggressive most cancers stroma. miR-215 in the tumor tissue-derived sEVs (however not circulating sEVs) was correlated with poor general survival of sufferers with HNSCC. This examine demonstrated that sEVs perform as a “courier” to ship miRNAs from the most cancers cells to the fibroblasts, which promotes the reworking of the hypoxic tumor microenvironment, and that most cancers tissue-derived sEV may doubtlessly function a supply of biomarker.
The intention of this examine was to analyze utilizing myogenic differentiation of adipose stem cells for the remedy of feminine pelvic ground dysfunction (PFD) and aimed to additional examine the influences of microRNA-124-3p (miR-124-3p) in the method of myogenic differentiation of adipose-derived stem cells (ADSCs) via concentrating on Caveolin-1 (Cav1) throughout PFD in Sprague Dawley (SD) rats.
Comprehensive evaluation of lncRNA-associated ceRNA community reveals the novel potential of lncRNA, miRNA and mRNA biomarkers in human rectosigmoid junction most cancers
Although accumulating proof has confirmed the potential organic capabilities of lengthy non-coding RNAs (lncRNAs) as aggressive endogenous RNAs (ceRNAs) in colorectal tumorigenesis and development, few research have targeted on rectosigmoid junction most cancers. In the current examine, a complete evaluation was carried out to discover lncRNA-mediated ceRNA implications and their potential worth for prognosis. lncRNA, microRNA (miR/miRNA) and mRNA expression profiles had been downloaded from The Cancer Genome Atlas database.
Subsequently, a lncRNA-miRNA-mRNA regulatory community was constructed to guage the capabilities of those differentially expressed genes on general survival (OS) for rectosigmoid junction most cancers. As a outcome, a rectosigmoid junction cancer-specific ceRNA community was efficiently constructed with 7 differentially expressed (DE)lncRNAs, 16 DEmiRNAs and 71 DEmRNAs. Among the community, one DElncRNA (small nucleolar RNA host gene 20) and three mRNAs (sodium- and chloride-dependent taurine transporter, fibroblast progress issue 13 and tubulin polyglutamylase TTLL7) had been considerably related to OS (P<0.05).
Additionally, two lncRNAs (KCNQ1OT1 and MIR17HG) interacted with many of the DEmiRNAs. Notably, two top-ranked miRNAs (hsa-miR-374a-5p and hsa-miR-374b-5p) related networks had been recognized to be markedly related to the pathogenesis. Furthermore, 4 DEmRNAs (caveolin-1, MET, filamin-A and AKT3) had been enriched in the Kyoto Encylopedia of Gene and Genomes pathway evaluation, in addition to being included in the ceRNA community. In abstract, the current outcomes revealed {that a} particular lncRNA-miRNA-mRNA community was related to rectosigmoid junction most cancers, offering a number of molecules that could be used as novel prognostic biomarkers and therapeutic targets.
Endocytic pathway inhibition attenuates extracellular vesicle-induced discount of chemosensitivity to bortezomib in a number of myeloma cells
Extracellular vesicles (EVs), together with exosomes and microvesicles, derived from bone marrow stromal cells (BMSCs) have been demonstrated as key components in the development and drug resistance of a number of myeloma (MM). EV uptake entails a wide range of mechanisms which largely depend upon the vesicle origin and recipient cell kind. The intention of the current examine was to establish the mechanisms concerned in the uptake of BMSC-derived small EVs (sEVs) by MM cells, and to guage the anti-MM impact of concentrating on this course of.
Human BMSC-derived sEVs had been recognized by transmission electron microscopy, nanoparticle monitoring evaluation, and western blot. The results of chemical inhibitors and shRNA-mediated knockdown of endocytosis-associated genes on sEV uptake and cell apoptosis had been analyzed by circulation cytometry. The anti-MM impact of blocking sEV uptake was evaluated in vitro and in a xenograft MM mouse mannequin.
sEVs derived from BMSC had been taken up by MM cells in a time- and dose-dependent method, and subsequently promoted MM cell biking and decreased their chemosensitivity to bortezomib. Chemical endocytosis inhibitors concentrating on heparin sulphate proteoglycans, actin, tyrosine kinase, dynamin-2, sodium/proton exchangers, or phosphoinositide 3-kinases considerably decreased MM cell internalization of BMSC-derived sEVs.
Moreover, shRNA-mediated knockdown of endocytosis-associated proteins, together with caveolin-1, flotillin-1, clathrin heavy chain, and dynamin-2 in MM cells suppressed sEV uptake. Furthermore, an endocytosis inhibitor concentrating on dynamin-2 preferentially suppressed the uptake of sEV by major MM cells ex vivo and enhanced the anti-MM results of bortezomib in vitro and in a mouse mannequin. Clathrin- and caveolin-dependent endocytosis and macropinocytosis are the predominant routes of sEV-mediated communication between BMSCs and MM cells, and inhibiting endocytosis attenuates sEV-induced discount of chemosensitivity to bortezomib, and thus enhances its anti-MM properties.
 Caveolin-1 Antibody |
|
AF0126 |
Affbiotech |
200ul |
EUR 304 |
|
Description: Caveolin-1 antibody detects endogenous levels of total Caveolin-1. |
 anti-Caveolin 1 |
|
YF-PA10691 |
Abfrontier |
100 ug |
EUR 403 |
|
Description: Rabbit polyclonal to Caveolin 1 |
Caveolin-1 Antibody |
|
A1010-50 |
Biovision |
|
EUR 403 |
 Caveolin 1 antibody |
|
20R-1949 |
Fitzgerald |
50 ug |
EUR 281 |
|
Description: Rabbit polyclonal Caveolin 1 antibody |
Caveolin 1 antibody |
|
20R-2291 |
Fitzgerald |
50 ug |
EUR 281 |
|
Description: Rabbit polyclonal Caveolin 1 antibody |
 Caveolin-1 Peptide |
|
45-027P |
ProSci |
0.1 mg |
EUR 338 |
|
Description: (IN) Caveolin-1 Peptide |
Caveolin-1 Peptide |
|
8219P |
ProSci |
0.05 mg |
EUR 164.75 |
|
Description: Caveolin-1 Peptide |
Caveolin 1 antibody |
|
70R-31113 |
Fitzgerald |
100 ug |
EUR 327 |
|
Description: Rabbit polyclonal Caveolin 1 antibody |
Caveolin 1 antibody |
|
70R-35767 |
Fitzgerald |
100 ug |
EUR 327 |
|
Description: Rabbit polyclonal Caveolin 1 antibody |
Caveolin 1 antibody |
|
70R-49479 |
Fitzgerald |
100 ul |
EUR 244 |
|
Description: Purified Polyclonal Caveolin 1 antibody |
Caveolin 1 antibody |
|
70R-49480 |
Fitzgerald |
100 ul |
EUR 244 |
|
Description: Purified Polyclonal Caveolin 1 antibody |
Caveolin-1 Antibody |
|
8219-002mg |
ProSci |
0.02 mg |
EUR 171.82 |
|
|
|
Description: Caveolin-1 Antibody: Caveolin-1 is a scaffolding protein that is the main component of the caveolae plasma membranes found in most cell types (1). The protein links integrin subunits to the tyrosine kinase FYN, an initiating step in coupling integrins to the Ras-ERK pathway and promoting cell cycle progression (2). The gene is a tumor suppressor gene candidate and a negative regulator of the Ras-p42/44 mitogen-activated kinase cascade (3). Mutations in this gene have been associated with Berardinelli-Seip congenital lipodystrophy (4). |
Caveolin-1 Antibody |
|
8219-01mg |
ProSci |
0.1 mg |
EUR 436.42 |
|
|
|
Description: Caveolin-1 Antibody: Caveolin-1 is a scaffolding protein that is the main component of the caveolae plasma membranes found in most cell types (1). The protein links integrin subunits to the tyrosine kinase FYN, an initiating step in coupling integrins to the Ras-ERK pathway and promoting cell cycle progression (2). The gene is a tumor suppressor gene candidate and a negative regulator of the Ras-p42/44 mitogen-activated kinase cascade (3). Mutations in this gene have been associated with Berardinelli-Seip congenital lipodystrophy (4). |
) Dog Caveolin-1 (CAV1) |
|
1-CSB-YP004571DO |
Cusabio |
-
EUR 679.00
-
EUR 335.00
-
EUR 2172.00
-
EUR 1051.00
-
EUR 1442.00
-
EUR 435.00
|
- 100ug
- 10ug
- 1MG
- 200ug
- 500ug
- 50ug
|
|
|
|
Description: Recombinant Dog Caveolin-1(CAV1) expressed in Yeast |
) Recombinant Caveolin 1 (CAV1) |
|
4-RPA214Hu01 |
Cloud-Clone |
-
EUR 522.91
-
EUR 243.00
-
EUR 1685.92
-
EUR 628.64
-
EUR 1157.28
-
EUR 413.00
-
EUR 4064.80
|
- 100 ug
- 10ug
- 1 mg
- 200 ug
- 500 ug
- 50ug
- 5 mg
|
|
|
|
Description: Recombinant Human Caveolin 1 expressed in: E.coli |
Recombinant Caveolin 1 (CAV1) |
|
4-RPA214Mu01 |
Cloud-Clone |
-
EUR 565.92
-
EUR 254.00
-
EUR 1847.20
-
EUR 682.40
-
EUR 1264.80
-
EUR 442.00
-
EUR 4468.00
|
- 100 ug
- 10ug
- 1 mg
- 200 ug
- 500 ug
- 50ug
- 5 mg
|
|
|
|
Description: Recombinant Mouse Caveolin 1 expressed in: E.coli |
Recombinant Caveolin 1 (CAV1) |
|
4-RPA214Ra01 |
Cloud-Clone |
-
EUR 637.60
-
EUR 274.00
-
EUR 2116.00
-
EUR 772.00
-
EUR 1444.00
-
EUR 490.00
-
EUR 5140.00
|
- 100 ug
- 10ug
- 1 mg
- 200 ug
- 500 ug
- 50ug
- 5 mg
|
|
|
|
Description: Recombinant Rat Caveolin 1 expressed in: E.coli |
 Caveolin-1 Polyclonal Antibody |
|
ES1872-100ul |
ELK Biotech |
100ul |
EUR 279 |
|
Description: A Rabbit Polyclonal antibody against Caveolin-1 from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, WB, ELISA |
Caveolin-1 Polyclonal Antibody |
|
ES1872-50ul |
ELK Biotech |
50ul |
EUR 207 |
|
Description: A Rabbit Polyclonal antibody against Caveolin-1 from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, WB, ELISA |
Caveolin-1 Polyclonal Antibody |
|
ES1873-100ul |
ELK Biotech |
100ul |
EUR 279 |
|
Description: A Rabbit Polyclonal antibody against Caveolin-1 from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, IHC, IF, WB, ELISA |
Caveolin-1 Polyclonal Antibody |
|
ES1873-50ul |
ELK Biotech |
50ul |
EUR 207 |
|
Description: A Rabbit Polyclonal antibody against Caveolin-1 from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, IHC, IF, WB, ELISA |
 Polyclonal Caveolin-1 Antibody |
|
APG02445G |
Leading Biology |
0.05ml |
EUR 528 |
|
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human Caveolin-1 . This antibody is tested and proven to work in the following applications: |
Polyclonal Caveolin-1 Antibody |
|
APG02446G |
Leading Biology |
0.1ml |
EUR 484 |
|
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human Caveolin-1 . This antibody is tested and proven to work in the following applications: |
Caveolin-1 Polyclonal Antibody |
|
ABP50873-003ml |
Abbkine |
0.03ml |
EUR 158 |
|
|
|
Description: A polyclonal antibody for detection of Caveolin-1 from Human, Mouse, Rat. This Caveolin-1 antibody is for WB, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human Caveolin-1 around the non-phosphorylation site of Y14 |
Caveolin-1 Polyclonal Antibody |
|
ABP50873-01ml |
Abbkine |
0.1ml |
EUR 289 |
|
|
|
Description: A polyclonal antibody for detection of Caveolin-1 from Human, Mouse, Rat. This Caveolin-1 antibody is for WB, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human Caveolin-1 around the non-phosphorylation site of Y14 |
Caveolin-1 Polyclonal Antibody |
|
ABP50873-02ml |
Abbkine |
0.2ml |
EUR 414 |
|
|
|
Description: A polyclonal antibody for detection of Caveolin-1 from Human, Mouse, Rat. This Caveolin-1 antibody is for WB, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human Caveolin-1 around the non-phosphorylation site of Y14 |
Caveolin-1 Polyclonal Antibody |
|
ABP50874-003ml |
Abbkine |
0.03ml |
EUR 158 |
|
|
|
Description: A polyclonal antibody for detection of Caveolin-1 from Human, Mouse, Rat. This Caveolin-1 antibody is for WB, IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human Caveolin-1 at AA range: 100-180 |
Caveolin-1 Polyclonal Antibody |
|
ABP50874-01ml |
Abbkine |
0.1ml |
EUR 289 |
|
|
|
Description: A polyclonal antibody for detection of Caveolin-1 from Human, Mouse, Rat. This Caveolin-1 antibody is for WB, IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human Caveolin-1 at AA range: 100-180 |
Caveolin-1 Polyclonal Antibody |
|
ABP50874-02ml |
Abbkine |
0.2ml |
EUR 414 |
|
|
|
Description: A polyclonal antibody for detection of Caveolin-1 from Human, Mouse, Rat. This Caveolin-1 antibody is for WB, IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human Caveolin-1 at AA range: 100-180 |
 Antibody) Caveolin 1 (CAV1) Antibody |
|
20-abx116788 |
Abbexa |
|
|
|
|
Caveolin 1 (CAV1) Antibody |
|
abx122002-100ug |
Abbexa |
100 ug |
EUR 391 |
|
|
Caveolin 1 (CAV1) Antibody |
|
20-abx125305 |
Abbexa |
-
EUR 495.00
-
EUR 704.00
-
EUR 356.00
|
|
|
|
Caveolin 1 (CAV1) Antibody |
|
20-abx100474 |
Abbexa |
-
EUR 398.00
-
EUR 133.00
-
EUR 1107.00
-
EUR 537.00
-
EUR 314.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
|
Caveolin 1 (CAV1) Antibody |
|
20-abx100475 |
Abbexa |
-
EUR 411.00
-
EUR 133.00
-
EUR 1135.00
-
EUR 551.00
-
EUR 314.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
|
Caveolin 1 (CAV1) Antibody |
|
20-abx100476 |
Abbexa |
-
EUR 425.00
-
EUR 133.00
-
EUR 1177.00
-
EUR 578.00
-
EUR 328.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
|
 Caveolin 1 Blocking Peptide |
|
20-abx062354 |
Abbexa |
|
|
|
|
Caveolin 1 Blocking Peptide |
|
20-abx062355 |
Abbexa |
|
|
|
|
 Antibody) Caveolin-1 (CAV1) Antibody |
|
20-abx137365 |
Abbexa |
-
EUR 704.00
-
EUR 328.00
-
EUR 230.00
|
|
|
|
Caveolin 1 (CAV1) Antibody |
|
20-abx000539 |
Abbexa |
-
EUR 411.00
-
EUR 592.00
-
EUR 314.00
|
|
|
|
Caveolin 1 (CAV1) Antibody |
|
20-abx009491 |
Abbexa |
-
EUR 300.00
-
EUR 439.00
-
EUR 189.00
|
|
|
|
Caveolin 1 (CAV1) Antibody |
|
20-abx009492 |
Abbexa |
-
EUR 300.00
-
EUR 439.00
-
EUR 189.00
|
|
|
|
 Antibody) Caveolin 1 (pT14) Antibody |
|
20-abx009682 |
Abbexa |
-
EUR 314.00
-
EUR 467.00
-
EUR 203.00
|
|
|
|
 Antibody) Caveolin 1 (pY14) Antibody |
|
abx010493-100ug |
Abbexa |
100 ug |
EUR 439 |
|
|
Caveolin 1 (CAV1) Antibody |
|
20-abx013031 |
Abbexa |
-
EUR 314.00
-
EUR 98.00
-
EUR 398.00
-
EUR 495.00
|
- 100 ug
- 10 ug
- 200 ug
- 300 µg
|
|
|
Caveolin 1 (CAV1) Antibody |
|
abx019037-100ug |
Abbexa |
100 ug |
EUR 342 |
|
|
 Caveolin-1 Rabbit mAb |
|
A19006-100ul |
Abclonal |
100 ul |
EUR 410 |
Caveolin-1 Rabbit mAb |
|
A19006-200ul |
Abclonal |
200 ul |
EUR 571 |
Caveolin-1 Rabbit mAb |
|
A19006-20ul |
Abclonal |
20 ul |
EUR 221 |
Caveolin-1 Rabbit mAb |
|
A19006-50ul |
Abclonal |
50 ul |
EUR 287 |
Caveolin 1 (CAV1) Antibody |
|
abx431142-200ul |
Abbexa |
200 ul |
EUR 384 |
|
|
) Caveolin 1 Antibody (Biotin) |
|
abx431143-200ul |
Abbexa |
200 ul |
EUR 384 |
|
|
Caveolin 1 (CAV1) Antibody |
|
20-abx241052 |
Abbexa |
|
|
|
|
) Caveolin 1 Protein (OVA) |
|
20-abx165517 |
Abbexa |
-
EUR 578.00
-
EUR 258.00
-
EUR 1720.00
-
EUR 690.00
-
EUR 425.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
|
Caveolin 1 (CAV1) Antibody |
|
20-abx242330 |
Abbexa |
|
|
|
|
Caveolin 1 (CAV1) Antibody |
|
20-abx175748 |
Abbexa |
|
|
|
|
Caveolin 1 (CAV1) Antibody |
|
20-abx175750 |
Abbexa |
-
EUR 425.00
-
EUR 133.00
-
EUR 1191.00
-
EUR 578.00
-
EUR 328.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
|
Caveolin 1 (CAV1) Antibody |
|
20-abx175751 |
Abbexa |
|
|
|
|
Caveolin 1 (CAV1) Antibody |
|
20-abx175752 |
Abbexa |
|
|
|
|
Caveolin 1 (CAV1) Antibody |
|
20-abx175753 |
Abbexa |
|
|
|
|
Caveolin 1 (CAV1) Antibody |
|
20-abx175754 |
Abbexa |
|
|
|
|
Caveolin 1 (CAV1) Antibody |
|
20-abx175755 |
Abbexa |
|
|
|
|
Caveolin 1 (CAV1) Antibody |
|
20-abx175756 |
Abbexa |
|
|
|
|
Caveolin 1 (CAV1) Antibody |
|
20-abx171646 |
Abbexa |
|
|
|
|
Caveolin 1 (CAV1) Antibody |
|
20-abx171647 |
Abbexa |
|
|
|
|
Caveolin 1 (CAV1) Antibody |
|
20-abx171648 |
Abbexa |
|
|
|
|
Caveolin 1 (CAV1) Antibody |
|
20-abx171649 |
Abbexa |
|
|
|
|
Caveolin-1 (CAV1) Antibody |
|
abx231313-100ug |
Abbexa |
100 ug |
EUR 481 |
|
|
Caveolin-1 (CAV1) Antibody |
|
abx231314-100ug |
Abbexa |
100 ug |
EUR 481 |
|
|
Caveolin 1 (CAV1) Antibody |
|
abx330500-100ul |
Abbexa |
100 ul |
EUR 425 |
|
|
Caveolin 1 (CAV1) Antibody |
|
abx332130-100ul |
Abbexa |
100 ul |
EUR 425 |
|
|
Caveolin 1 (CAV1) Antibody |
|
20-abx327354 |
Abbexa |
|
|
|
|
Caveolin 1 (CAV1) Antibody |
|
20-abx328161 |
Abbexa |
|
|
|
|
 Anti-Caveolin-1 antibody |
|
STJ92050 |
St John's Laboratory |
200 µl |
EUR 197 |
|
Description: Rabbit polyclonal to Caveolin-1. |
Anti-Caveolin-1 antibody |
|
STJ92051 |
St John's Laboratory |
200 µl |
EUR 197 |
|
Description: Caveolin-1 is a protein encoded by the CAV1 gene which is approximately 20,4 kDa. Caveolin-1 is localised to the Golgi apparatus membrane and cell membrane. It is involved in eNOS activation and regulation, focal adhesion and lipoprotein metabolism. It is a scaffolding protein that makes up the main component of the caveolae plasma membranes found in most cell types. The protein links integrin subunits to the tyrosine kinase FYN which is an initiating step in coupling integrins to the Ras-ERK pathway and promoting cell cycle progression. Caveolin-1 is expressed in the brain. Mutations in the CAV1 gene may result in pulmonary hypertension and lipodystrophy. STJ92051 was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. This polyclonal antibody detects endogenous levels of Caveolin-1 protein. |
 anti- Caveolin-1 antibody |
|
FNab01313 |
FN Test |
100µg |
EUR 505.25 |
|
|
|
Description: Antibody raised against Caveolin-1 |
anti- Caveolin-1 antibody |
|
FNab01314 |
FN Test |
100µg |
EUR 505.25 |
|
|
|
Description: Antibody raised against Caveolin-1 |
Caveolin-1 Polyclonal Antibody |
|
40684-100ul |
SAB |
100ul |
EUR 252 |
Caveolin-1 Polyclonal Antibody |
|
40684-50ul |
SAB |
50ul |
EUR 187 |
 Recombinant human Caveolin-1 |
|
P1754 |
FN Test |
100ug |
Ask for price |
|
|
|
Description: Recombinant protein for human Caveolin-1 |
 Caveolin-1 Conjugated Antibody |
|
C48674 |
SAB |
100ul |
EUR 397 |
Caveolin 1 Blocking Peptide |
|
AF5372-BP |
Affbiotech |
1mg |
EUR 195 |
 Caveolin-1 Blocking Peptide |
|
AF6386-BP |
Affbiotech |
1mg |
EUR 195 |
Caveolin-1 Blocking Peptide |
|
AF0126-BP |
Affbiotech |
1mg |
EUR 195 |
) Caveolin 1 antibody (Tyr14) |
|
70R-35245 |
Fitzgerald |
100 ug |
EUR 327 |
|
Description: Purified Rabbit polyclonal Caveolin 1 antibody (Tyr14) |
 Caveolin antibody |
|
10R-10553 |
Fitzgerald |
100 ug |
EUR 349 |
|
Description: Mouse monoclonal Caveolin antibody |
) OVA conjugated Caveolin 1 (CAV1) |
|
4-CPA214Hu21 |
Cloud-Clone |
-
EUR 413.60
-
EUR 214.00
-
EUR 1276.00
-
EUR 492.00
-
EUR 884.00
-
EUR 340.00
-
EUR 3040.00
|
- 100 ug
- 10ug
- 1 mg
- 200 ug
- 500 ug
- 50ug
- 5 mg
|
|
|
|
Description: Recombinant Human Caveolin 1 expressed in: Protein conjugation |
 Anti-Caveolin-1/CAV1 Antibody |
|
PA1514 |
BosterBio |
100ug/vial |
EUR 334 |
Moreover, genetic deletion of caveolin-1 or pharmacological blockade of Tie2 signaling successfully normalizes microvascular construction and barrier perform with attenuated EC-pericyte disassociation and CCM lesion formation in Pdcd10BECKO mice. Our examine establishes a persistent CCM mannequin and uncovers a mechanism by which CCM3 mutation-induced caveolae-Tie2 signaling contributes to CCM pathogenesis.
